Evaluating cost benefits of combination therapies for advanced melanoma

BACKGROUND: Although a number of monoimmunotherapies and targeted therapies are available to treat BRAF+ advanced melanoma, response rates remain relatively low in the range of 22–53% with progression-free survival (PFS) in the range of 4.8–8.8 months. Recently, combination targeted therapies have i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Ivar S., Zacherle, Emily, Blanchette, Christopher M., Zhang, Jie, Yin, Wes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Just Medical Media Limited 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974051/
https://www.ncbi.nlm.nih.gov/pubmed/27540409
http://dx.doi.org/10.7573/dic.212297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974051/
https://www.ncbi.nlm.nih.gov/pubmed/27540409
http://dx.doi.org/10.7573/dic.212297

Ejemplares similares